Complement Mediated Rare Disease

One Day Conference – The Complement Cascade: Fundamentals and Emerging Therapeutics

This one-day accredited conference, co-developed and delivered by the Canadian Institute for the Transfer of Knowledge (CITE), Canadian Hematology Society (CHS), and Continuing Professional Development (CPD), Faculty of Health Sciences, McMaster University, took place on September 20th, 2025.

The program focused on the identification and management of complement related diseases and was certified by the CFPC (up to 5.0 Mainpro+ Certified Activity credits) and the RCPSC (maximum 5.0 MOC Section 1 hours).

To access the conference recordings, please utilize the link below:

https://vimeopro.com/user41835743/day-in-complement-2025/video/1125927632

Password: Complement2025

Target Audience:

This program is designed for a diverse range of healthcare professionals involved in the diagnosis, management, and research of complement-mediated diseases.

Learning Objectives

By the end of this activity, participants will be able to:

Describe the structure, function, and regulatory mechanisms of the complement cascade in health and disease.
Analyze the clinical manifestations and diagnostic implications of complement dysregulation in diseases such as PNH and aHUS.
Evaluate current and emerging complement-targeted therapies for their clinical applicability and efficacy.
Discuss multidisciplinary and patient-centered approaches to managing complement-mediated disorders.
Reflect on the future

Agenda:

Complement 101 – Basics of the Complement Cascade

Speaker: Chris Patriquin

Complement pathways, functions, and regulatory mechanisms

View Slides

Complement Pathologies – When Regulation Fails

Speaker: Shruti Chaturvedi

Mechanisms of dysregulation and clinical consequences

View Slides

Clinical Insights – A rapid run through the Diseases with Complement-Mediated Pathogenesis

Speaker: Benjamin Chin-Yee

A “100,000 foot” overview of the various disease states that are felt to have a complement-mediated component

Coming Soon

The Future of Complement – Targeted Therapies

Panel (Moderator: Mark Crowther)

Industry and academic leaders discuss trends, challenges, and breakthroughs

No Slides

Breakout Session One: Optimizing PNH Management

Speaker: Chris Patriquin

Critical Pearls in the Understanding of the Complement Cascade – An advanced perspective on complement regulation

View Slides

Breakout Session Two: Targeting Complement in aHUS

Speaker: Christoph Licht

View Slides

Breakout Session Three: Insights into current and future Therapies for Complement Disorders

(Other than PNH and aHUS)

Speaker: Shruti Chaturvedi

View Slides

Funding provided by Alexion, Novartis, Roche, and Sobi as an educational grant for knowledge translation activities in Complement Mediated Rare Disease in partnership with CITE and CHS.

Paroxysmal Nocturnal Hemoglobinuria: An Individualized Approach to Care

After participating in this multidisciplinary program, participants will be better able to;

Describe the underlying mechanisms and clinical consequences of PNH including how IVH contributes to morbidity and mortality;
Evaluate current and emerging therapeutic strategies for PNH management including how the MOA of different therapeutic targets modulates complement activity;
Interpret key clinical considerations in PNH management, such as selecting therapies based on patient presentations that impact treatment choice;
Examine strategies for PNH patients with suboptimal responses to treatment including managing BTH and EVH.

Speakers:

Robert A. Brodsky, MD
Director, Division of Hematology
Program Director, T32 Training Program,
Division of Hematology
Johns Hopkins Family Professor of Oncology Research

Funding provided by Alexion, Novartis, Roche, and Sobi as an educational grant for knowledge translation activities in Complement Mediated Rare Disease in partnership with CITE and CHS.

CLINICAL GUIDE: Atypical hemolytic uremic syndrome (aHUS)

Coming Soon

CLINICAL GUIDE: Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria (BTH in PNH)

Coming Soon

Authors: Marc Bienz, MD, and Benjamin Chin-Yee, MD

Funding provided by Alexion, Novartis, Roche, and Sobi as an educational grant for knowledge translation activities in Complement Mediated Rare Disease in partnership with CITE and CHS.